References
- 1. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108.10.3322/canjclin.55.2.7415761078
- 2. Hashem B. El-Serag. Hepatocellular Carcinoma. N Engl J Med 2011; 365: 1118–1127 DOI: 10.1056/NEJMra100168310.1056/NEJMra100168321992124
- 3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.10.1053/j.gastro.2007.04.06117570226
- 4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology : WJG. 2008; 14(27):4 300–4308. doi:10.3748/wjg.14.4300.10.3748/wjg.14.4300273118018666317
- 5. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From Cirrhosis to Hepatocellular Carcinoma: New Molecular In sights on Inflammation and Cellular Senescence. Liver Cancer. 2013; 2(3–4): 367–383. doi:10.1159/000343852.10.1159/000343852388131924400224
- 6. Gilgenkrantz H, de l’Hortet AC. New insights into liver regeneration. Clin Res Hepatol Gastroenterol. 2011; 35: 623–9. DOI:10.1016/j.clinre.2011.04.002.10.1016/j.clinre.2011.04.00221613004
- 7. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol. 2012; 57: 692–4. DOI:10.1002/hep.20969.10.1002/hep.2096916447274
- 8. Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014 Jan; 49(1): 9-23. doi: 10.1007/s00535-013-0907-x.10.1007/s00535-013-0907-x24318021
- 9. Gea VH, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144(3): 512–27.10.1053/j.gastro.2013.01.002357806823313965
- 10. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res. 2013; 1(19): 2810–6.10.1158/1078-0432.CCR-12-196123549874
- 11. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013; 2013: 187204.10.1155/2013/187204359118023533994
- 12. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012; 56: 769–75.10.1002/hep.25670408715922378017
- 13. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17; 366(1): 2–16.10.1016/j.gene.2005.10.01816377102
- 14. Hirsh FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene2009; 28: S32–S37. Doi:10.1038/onc.2009.199.10.1038/onc.2009.19919680294
- 15. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein over-expression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006 Mar 1; 118(5): 1173–80.10.1002/ijc.2145416161046
- 16. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997; 17: 177–82. PMID: 929848710.1111/j.1600-0676.1997.tb00803.x9298487
- 17. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;26(25): 3787–800. DOI: 10.1038/sj.onc.120955610.1038/sj.onc.120955616799620
- 18. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193–199. PMID:11925590.10.3748/wjg.v8.i2.193465834911925590
- 19. Zhu AX, Rosmorduc O, Evans J.T.R., Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: A Phase III, Randomized, Double-Blind,Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. J Clin Oncol 2015; 33: 559–566.10.1200/JCO.2013.53.774625547503
- 20. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti K3, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 January; 16(1): 15–31. doi:10.1517/14728222.2011.648617.10.1517/14728222.2011.648617329178722239438
- 21. Wu X and Li Y. Signaling Pathways in Liver Cancer, in Alexander Julianov. Liver Tumors. IntechOpen, February 3rd 2012. DOI: 10.5772/31381. Available from: https://www.intechopen.com/books/liver-tumors/signaling-pathways-in-liver-cancer.10.5772/31381.Availablefrom:https://www.intechopen.com/books/liver-tumors/signaling-pathways---
- 22. Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, et al. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel). 2011 May 18; 3(2): 2444–61. doi: 10.3390/cancers3022444.10.3390/cancers3022444
- 23. Jorissen R.N, Walker F, Pouliot, N, Garrett T.P, Ward C.W, Burgess A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003; 284, 31–53.10.1016/S0014-4827(02)00098-8
- 24. Citri A, Yarden Y. EGF-ErbB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006; 7, 505–516.10.1038/nrm1962
- 25. Schneider M.R, Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 2009; 218, 460–466.10.1002/jcp.21635
- 26. Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci. 2015 Dec 29; 17(1). pii: E30. doi: 10.3390/ijms17010030.10.3390/ijms17010030
- 27. Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology. 2002; 123: 2017–27.10.1053/gast.2002.37060
- 28. Berasain C, Perugorrıa MJ, Latasa MU, Castillo J, Goni S, Santamaría M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009; 234: 713–25.10.3181/0901-MR-12
- 29. Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000 Jun; 48(6): 821–30. DOI:10.1177/002215540004800610.10.1177/002215540004800610
- 30. Qiao Q, Zhang J, Wang W, Li Q. Over expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology. 2008 Jan-Feb; 55(81): 169–72. PMID:18507100.
- 31. Mantovani A, Allavena P, Sica A, BalkwillF. Cancer-related inflammation. Nature 2008; 454: 436–444 doi:10.1038/nature07205.10.1038/07205
- 32. Uslu S, Kirimlioglu H, Ince U. Analysis of Epidermal Growth Factor Receptor Expression in Hepatocellular Carcinoma: A Comparision of Fluorescence in Situ Hybridization and Immunochemistry. J Gastroenterol Hepatol Res 2014; 3(8): 1193–1197 URL: http://www.ghrnet.org/index.php/joghr/article/view/815.
- 33. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K et al. Expression and clinical significance of ErbB receptor family in hepatocellular carcinoma. Br. J. Cancer 2001; 84, 1377–1383. DOI:10.1054/bjoc.2000.1580.10.1054/bjoc.2000.1580
- 34. Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, et al. Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinogenes. 2003; 36, 130–141. doi.org/10.1002/mc.10103.10.1002/mc.10103
- 35. DeCicco LA, Kong J, Ringer DP.Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Lett. 1997 Jan 1; 111(1–2): 149–56.10.1016/S0304-3835(96)04524-7
- 36. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues. BioMed Research International,Volume 2015, Article ID 171845, 7 pages http://dx.doi.org/10.1155/2015/17184510.1155/2015/171845457598526436086
- 37. Ali R, Wendt MK. The paradoxa functions of EGFR during breast cancer progression. Signal Transduction and Targeted Therapy, volume 2 Article number: 16042 (2017) doi:10.1038/sigtrans.2016.42.10.1038/sigtrans.2016.42539711928435746
- 38. Whittaker S, Marais R, Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010 Sep 9; 29(36): 4989–5005. doi: 10.1038/onc.2010.236. Epub 2010 Jul 19.10.1038/onc.2010.236.Epub2010Jul19
- 39. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK.Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1): 15–31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12.10.1517/14728222.2011.648617.Epub201212
- 40. Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion. 2017; 96(1): 1-4. doi: 10.1159/000464282. Epub 2017 Jun 13.2860574510.1159/000464282.Epub201713